FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

43 letters match. Newest first.

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  3. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  4. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  5. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  6. Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.

    Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.

    High risk
  7. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  8. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  9. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  10. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  11. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  12. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  13. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  14. Lovelace Biomedical Research Institute

    Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

    Medium
  15. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  16. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk
  17. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  18. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  19. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  20. Curia New York, Inc.

    FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

    High risk
  21. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  22. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk
  23. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  24. NexCell Scientific Inc

    NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.

    High risk
  25. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  26. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk
  27. Happy Farm Botanicals, Inc.

    Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.

    High risk
  28. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  29. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk
  30. Reliance Life Sciences Private Limited

    FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.

    High risk
  31. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  32. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  33. R3 Medical Companies

    FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

    High risk
  34. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  35. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  36. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  37. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  38. FairyGene, Inc.

    FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.

    High risk
  39. Lico Industries, LLC., d.b.a. American Towelette Company

    FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.

    High risk
  40. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  41. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  42. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  43. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk